We are live on ! Find out more
MNPR icon

Monopar Therapeutics
MNPR

13 hedge funds and large institutions have $1.21M invested in Monopar Therapeutics in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

181% more capital invested

Capital invested by funds: $429K → $1.21M (+$778K)

86% more funds holding

Funds holding: 7 → 13 (+6)

0.19% more ownership

Funds ownership: 0.12% → 0.31% (+0.19%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
13
Holders Change
+6
Holders Change %
+85.71%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
+$348K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$329K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$193K
4
Citadel Advisors
Citadel Advisors
Florida
+$91.1K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$66.7K

Top Sellers

Rank Fund Capital Flow
1
Northern Trust
Northern Trust
Illinois
-$166K
2
UBS Group
UBS Group
Switzerland
-$2.77K

MNPR Hedge Fund Activity: Q1 2021 in Review

13 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q1 2021, worth a combined $1.21M — up 181% from $429K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new MNPR positions and 0 closed out — a net gain of 6 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Marshall Wace, opening a new position worth an estimated $348K. The largest seller was Northern Trust, cutting an estimated $166K.

  • 13 institutional investors held Monopar Therapeutics (MNPR) as of Q1 2021, up from 7 in Q4 2020.
  • Funds reported $1.21M of Monopar Therapeutics stock for Q1 2021, up 181% quarter-over-quarter.
  • 6 funds opened new Monopar Therapeutics positions in Q1 2021 and 0 closed out, a net change of +6 holders.
  • The largest Monopar Therapeutics buyer in Q1 2021 was Marshall Wace, an estimated $348K added.
  • The largest Monopar Therapeutics seller in Q1 2021 was Northern Trust, an estimated $166K sold.

Based on aggregated 13F filings for Q1 2021.